Market Report Source

Overview

CNS disorders constitute one of the most significant components of healthcare spending in the developed world, contributing to an estimated 35% of the disease burden within the seven major pharma markets. However, an increased presence of generic products and lack of innovative product launches have prompted a slowdown in market growth, which pharma and biotech companies are addressing through a shift in R&D focus towards disease areas with relatively low levels of innovation, such as Alzheimer’s and Parkinson’s disease.

The CNS Market Outlook to 2012 is a new report published by Business Insights that provides a detailed epidemiological analysis of major indications within the CNS disorders market, and examines the factors impacting their prevalence. The current opportunities and threats facing the market are assessed and the most promising potential growth areas across all indications are highlighted. The report also profiles the key trends influencing treatment sales and analyses the competitive dynamics of leading brands within each indication. Discover the key trends and growth drivers within the CNS market, assess the competitive dynamics of leading pharma companies and evaluate the future prospects of major products with this new report.

Table of Contents

Executive Summary
Patient potential
Global market analysis
Pipeline analysis
Competitive landscape

Chapter 1 Epidemiology of CNS disorders
Summary
Introduction
Alzheimer’s disease
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Major depressive disorder (MDD)
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Schizophrenia
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Migraine
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Epilepsy
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Parkinson’s disease
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology

Chapter 2 Global market analysis
Summary
Introduction
Market analysis by country
Licensing/generics trends
Market analysis by indication
Leading brands dynamics
Key events in the CNS disorders market,
Revised suicidal warning labeling for SSRI anti depressants
Increased risk of bone fractures associated with the use of SSRIs
Launch of Lyrica (pregabalin) as a replacement product for Pfizer’s Neurontin (gabapentin)
US FDA calls for voluntary withdrawal of all pergolide-based products
Launch for first transdermal patch formulation of Novartis’ Exelon for the treatment of AD
Arrival of generic competition to key products in the CNS market in 2005-6
Depression
Market analysis by drug class
Competitive dynamics of anti-depressants
Leading brands in the Anti-depressants market
Selective Serotonin Reuptake Inhibitors (SSRIs)
Market dynamics
Key brands analysis
Selective Norepinephrine Reuptake Inhibitors (SNRIs)
Key brands analysis
Others
Anti-depressants sales forecasts to 2012
Alzheimer’s disease
Market analysis by drug class
Competitive dynamics of subclasses of anti-Alzheimer’s disease
Leading brands in the Anti-Alzheimer’s market
Cholinesterase inhibitors market analysis
Market dynamics
Key brands analysis
NMDA receptor antagonists
Market dynamics
Key brands analysis
Anti-Alzheimer’s drugs sales forecasts to 2012
Epilepsy
Market analysis by drug class
Competitive dynamics of subclasses of anti-epileptics
Leading brands in the anti-epileptic market
Traditional anti-epileptics
Market dynamics
Key brands analysis
Second generation anti-epileptics market analysis
Market dynamics
Key brands analysis
Anti-epiletics sales forecasts to 2012
Migraine
Market analysis by drug class
Leading brands of anti migraine drugs
Triptans
Key brands analysis
Anti-migraine sales forecasts to 2012
Parkinson’s disease
Market analysis
Leading brands in the anti Parkinson’s market Table 2.30 summarizes the performance of the leading anti-Parkinson’s disease brands in 2005-6
COMT inhibitors
Key brands analysis
Dopaminergics
Key brands analysis
Dopamine Agonists
Key brands analysis
Anti-Parkinson’s drugs sales forecasts to 2012
Schizophrenia
Market analysis
Leading brands in the Schizophrenia market
Typical anti-psychotics
Atypical antipsychotics
Key brands analysis
Schizophrenia drugs sales forecasts to 2012
Total CNS disorders’ sales forecasts to 2012

Chapter 3 Pipeline analysis
Summary
Introduction
Key trends in R&D
New class of drugs
Dual mechanism of action
Combination drugs
New drug delivery formulations
The CNS disorders pipeline
Leading drugs in development
Profiles of key pipeline products
Phase II compounds
Ketasyn/AC-1202
PBT2 (Metal Protein Attenuating Compound)
Phase III compounds
vilazodone
ACP 103 (pimavanserin)
MK-0974
safinamide
Drugs in registration
DVS-233 (desvenlafaxine)
Trexima (sumatriptan/naproxen)
Vimpat (lacosamide)
Recently marketed drugs
Invega (paliperidone)
Neupro (rotigotine transdermal patch)
Inovelon (rufinamide)
Pipeline forecasts
CNS disorders pipeline forecasts

Chapter 4 Competitive landscape
Summary
Introduction
Company market shares
Johnson & Johnson
Overview
Sales focus by indication
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Sales and Promotion analysis
Drivers of growth
Resistors of growth
Glaxo SmithKline
Overview
Sales focus by indication
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Sales and Promotion analysis
Drivers of growth
Resistors of growth
Pfizer
Overview
Sales focus by indication
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Sales and Promotion analysis
Drivers of growth
Resistors of growth
Lilly
Overview
Sales focus by indication
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Sales and Promotion analysis
Drivers of growth
Resistors of growth
Sanofi Aventis
Overview
Sales focus by indication
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Sales and Promotion analysis
Drivers of growth
Resistors of growth
Novartis
Overview
Sales focus by indication
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Sales and Promotion analysis
Drivers of growth
Resistors of growth
AstraZeneca
Overview
Sales focus by indication
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Sales and Promotion analysis
Drivers of growth
Resistors of growth
Wyeth
Overview
Sales focus by indication
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Sales and Promotion analysis
Drivers of growth
Resistors of growth
Forest Labs
Overview
Sales focus by indication
Marketed product portfolio
R&D pipeline analysis
Sales and Promotion analysis
Drivers of growth
Resistors of growth

Chapter 5 Appendix
IMS data
N1 Anaesthetics – Includes Anaesthetics local, others
N2 Analgesics
Index

List of Figures
Figure 1.1: Typical treatment patterns in the treatment of Alzheimer’s disease
Figure 1.2: Typical treatment patterns in the treatment of MDD
Figure 1.3: Typical treatment patterns in the treatment of schizophrenia
Figure 1.4: Typical treatment patterns in the treatment of PD
Figure 2.5: Global CNS market share by geography, 2006
Figure 2.6: Sales of types of CNS disorder brands, 2005-06
Figure 2.7: Competitive dynamics of the global CNS market by indication, 2006
Figure 2.8: Competitive dynamics of the leading 10 brands in the global CNS market, 2006
Figure 2.9: Competitive dynamics of the global anti-depressant market, 2005-6
Figure 2.10: Competitive dynamics of the global AD market, 2005-6
Figure 2.11: Competitive dynamics of the global AED market, 2005-6
Figure 2.12: Competitive dynamics of the global schizophrenia market, 2005-6
Figure 3.13: Prevailing R&D approaches, 2006
Figure 3.14: The CNS pipeline by indication and stage of development, 2006
Figure 3.15: Leading recently launched products and late-stage R&D compounds indicated for the treatment of CNS disorders, 2006
Figure 4.16: Competitive dynamics of the leading players in the global CNS market, 2006
Figure 4.17: J&J’s CNS portfolio sales by indication, 2006
Figure 4.18: GSK’s CNS portfolio sales by indication, 2006
Figure 4.19: Pfizer’s CNS portfolio sales by indication, 2006
Figure 4.20: Lilly’s CNS portfolio sales by indication, 2006
Figure 4.21: Sanofi Aventis’ CNS portfolio sales by indication, 2006
Figure 4.22: Novartis’ CNS portfolio sales by indication, 2006
Figure 4.23: AstraZenca’s CNS portfolio sales by indication, 2006
Figure 4.24: Wyeth’s CNS portfolio sales by indication, 2006
Figure 4.25: Forest Labs’ CNS portfolio sales by indication, 2006

List of Tables
Table 1.1: Estimated prevalence of CNS disorders across the seven major pharmaceutical markets, 2006
Table 1.2: Estimated prevalence of Alzheimer’s disease across seven major markets, 2006
Table 1.3: Forecast epidemiology of AD across the seven major markets, 2006-12
Table 1.4: Estimated prevalence of MDD across seven major markets, 2006
Table 1.5: Forecast epidemiology of MDD across the seven major markets, 2006-12
Table 1.6: Estimated prevalence of schizophrenia across seven major markets, 2006
Table 1.7: Forecast epidemiology of schizophrenia across seven major markets, 2006
Table 1.8: Estimated prevalence of migraine across seven major markets, 2006
Table 1.9: Forecast epidemiology of migraine across seven major markets, 2006
Table 1.10: Estimated prevalence of epilepsy across seven major markets, 2006
Table 1.11: Forecast epidemiology of epilepsy across seven major markets, 2006
Table 1.12: Estimated prevalence of PD across seven major markets, 2006
Table 1.13: Forecast epidemiology of PD across seven major markets, 2006
Table 2.14: Breakdown of the global CNS market by indication, 2002-06
Table 2.15: Leading brands in the global CNS disorders market, 2005–06
Table 2.16: Breakdown of the global anti-depressant market by drug class, 2002-06
Table 2.17: Leading anti-depressant products in the global CNS market, 2005–06
Table 2.18: Leading SSRI brands in the global CNS market, 2005–06
Table 2.19: Anti-depressants sales forecast, 2006-12
Table 2.20: Breakdown of the global anti-Alzheimer’s market by drug class, 2002-06
Table 2.21: Leading AD products in the global CNS market, 2005–06
Table 2.22: Anti-AD products’ sales forecast, 2006-12
Table 2.23: Breakdown of the global Epilepsy market by drug class, 2002-06
Table 2.24: Leading AED products in the global CNS market, 2005–06
Table 2.25: Anti-epileptics’ sales forecast, 2006-12
Table 2.26: Breakdown of the global migraine market by drug class, 2002-06
Table 2.27: Leading anti migraine products in the global CNS market, 2005–06
Table 2.28: Anti-migraine products’ sales forecast, 2006-12
Table 2.29: Breakdown of the global anti-PD market by drug class, 2002-06
Table 2.30: Leading brands in the global PD market, 2005–06
Table 2.31: Anti-PD products’ sales forecast, 2006-12
Table 2.32: Breakdown of the global schizophrenia market by drug class, 2002-06
Table 2.33: Leading products in the global schizophrenia market, 2005–06
Table 2.34: Schizophrenia products’ sales forecast, 2006-12
Table 2.35: CNS market sales forecasts by drug class, 2006-12
Table 3.36: CNS disorders pipeline forecasts, 2007-12
Table 4.37: Leading players in the global CNS disorders market, 2005-6
Table 4.38: J&J’s CNS product portfolio, 2005-6
Table 4.39: J&J’s CNS R&D product pipeline, 2006
Table 4.40: Promotional spends on major drugs by J&J, 2005-06
Table 4.41: GSK’s CNS product portfolio, 2005-06
Table 4.42: GSK’s CNS R&D product pipeline, 2006
Table 4.43: Promotional spends on major drugs by GSK, 2005-06
Table 4.44: Pfizer’s CNS product portfolio, 2005-6
Table 4.45: Pfizer’s CNS R&D product pipeline, 2006
Table 4.46: Promotional spends on major drugs by Pfizer, 2005-06
Table 4.47: Lilly’s CNS product portfolio, 2005-6
Table 4.48: Lilly’s CNS R&D product pipeline, 2006
Table 4.49: Promotional spends on major drugs by Lilly, 2005-06
Table 4.50: Sanofi Aventis’ CNS product portfolio, 2005-6
Table 4.51: Sanofi Aventis’ CNS R&D product pipeline, 2006
Table 4.52: Promotional spends on major drugs by Sanofi Aventis, 2005-06
Table 4.53: Novartis’ CNS product portfolio, 2005-6
Table 4.54: Novartis’ CNS R&D product pipeline, 2006
Table 4.55: Promotional spends on major CNS drugs by Novartis, 2005-06
Table 4.56: AstraZeneca’s CNS product portfolio, 2005-6
Table 4.57: AstraZeneca’s CNS R&D product pipeline, 2006
Table 4.58: Promotional spends on major CNS drugs by AstraZeneca, 2005-06
Table 4.59: Wyeth’s CNS product portfolio, 2005-6
Table 4.60: Wyeth’s CNS R&D product pipeline, 2006
Table 4.61: Promotional spends on major CNS drugs by Wyeth, 2005-06
Table 4.62: Forest Lab’s CNS product portfolio, 2005-6
Table 4.63: Forest Lab’s CNS R&D product pipeline, 2006
Table 4.64: Promotional spends on major CNS drugs by Forest, 2005-06